The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1/1b first-in-human study of IDRX-42, a novel oral tyrosine kinase inhibitor (TKI), in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GISTs).
 
Suzanne George
Stock and Other Ownership Interests - Abbott Laboratories
Honoraria - CStone Pharmaceuticals
Consulting or Advisory Role - Bayer; BioAtla; Blueprint Medicines; Daiichi; deciphera; Immunicum; Kayothera; Lilly; MORE Health; Research to Practice; UpToDate
Research Funding - BioAtla; Blueprint Medicines (Inst); Daiichi Sankyo RD Novare (Inst); Deciphera (Inst); Eisai (Inst); IDRx (Inst); Merck (Inst); SpringWorks Therapeutics (Inst); Theseus Pharmaceuticals (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - UptoDate
Expert Testimony - Bayer
Other Relationship - Research to Practice; WCG
 
George D. Demetri
Leadership - Blueprint Medicines; Translate BIO
Stock and Other Ownership Interests - Acrivon Therapeutics; Bessor Pharma; Blueprint Medicines; Caprion/HistoGeneX; Caris Life Sciences; Champions Oncology; Erasca, Inc; G1 Therapeutics; IDRx; Ikena Oncology; Kojin Therapeutics; Relay Therapeutics; Translate BIO
Consulting or Advisory Role - Acrivon Therapeutics; Arsenal Capital; Bayer; Blueprint Medicines; C4 Therapeutics; Caprion/HistoGeneX; Caris Life Sciences; Daiichi Sankyo; EMD Serono; Epizyme; G1 Therapeutics; GlaxoSmithKline; IDRx; Ikena Oncology; Janssen Oncology; Kojin Therapeutics; McCann Health; Medscape; Merck KGaA; Mirati Therapeutics; MJH Associates; Novartis; Pfizer; PharmaMar; Rain Therapeutics; Relay Therapeutics; Roche/Genentech; Synlogic; WIRB-Copernicus Group
Research Funding - Adaptimmune (Inst); Bayer (Inst); Daiichi Sankyo (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Patent on use of imatinib for GIST, receive minor royalty payment from Dana-Farber after license between Dana-Farber and Novartis
Travel, Accommodations, Expenses - Alexandria Real-Estate Summit
(OPTIONAL) Uncompensated Relationships - AACR; Alexandria Real-Estate Summit
 
Nick Lydon
Employment - IDRx
 
Vivek Kadambi
Employment - IDRx
 
Jessica Christo
Employment - IDRx
 
Debbie Johnson
Employment - IDRx
 
Patrick Schöffski
Honoraria - Blueprint Medicines
Consulting or Advisory Role - Adcendo; Blueprint Medicines; Boehringer Ingelheim; Cogent Biosciences; Deciphera; Eisai; Ellipses Pharma; Exelixis; Medpace; Merck; PharmaMar; SERVIER; SERVIER; SQZ Biotechnology; Studiecentrum voor Kernenergie (SCK CEN); Transgene
Research Funding - CoBioRes NV (Inst); Eisai (Inst); G1 Therapeutics (Inst); Genmab (Inst); Merck (Inst); ONA therapeutics (Inst); PharmaMar (Inst); Sartar Therapeutics (Inst)